Lil­ly touts topline late-phase da­ta for once-week­ly in­sulin in race to en­ter US mar­ket

As No­vo Nordisk stares down an FDA ad­comm lat­er this month to dis­cuss its once-week­ly in­sulin, Eli Lil­ly is work­ing on its own, shar­ing pos­i­tive …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.